3 deals
Investor · 3 deals
SymBiosis
Disclosed deals
Every published round SymBiosis took part in, and every parcel of existing shares it bought off another holder. Deals we hold but haven't published yet are not counted.
| Company | Stage | Announced | Amount | Role | Alongside | Sources |
|---|---|---|---|---|---|---|
| AdvanCell | Series D+ | 15 Jul 2026 | $450m | Participant | Startup Daily, Cut Through Venture, Forbes Australia (Mon 12 Oct 2026), Forbes Australia (Thu 3 Sep 2026), Forbes Australia (Thu 16 Jul 2026), Brandon Capital, advancell.com.au, Brandon Capital portfolio, Brandon Capital portfolio, Tenmile portfolio | |
| Spinifex Pharmaceuticals | Unnamed stage | Jul 2005 | $3.2m | Participant | bionity.com, GBS Ventures (Tue 30 Jun 2015), clinicalleader.com, GBS Ventures (Thu 3 Aug 2006), GBS Ventures (Tue 26 Jul 2005) | |
| AdvanCell | Series C | 12 Feb 2025 | $178m | Lead | Forbes Australia, SmartCompany, Startup Daily, Brandon Capital |
Portfolio
Companies SymBiosis has backed in a published round, and companies whose existing shares it bought off another holder.
| Company | What it does | First invested | Rounds | Led |
|---|---|---|---|---|
| AdvanCell | 12 Feb 2025, Series C | 2 | 1 | |
| Spinifex Pharmaceuticals | Jul 2005 | 1 | 0 |
Funds
Fund closes reported for SymBiosis, as distinct from the investments it has made.
Portfolio companies acquired
Companies SymBiosis has backed that another company then bought. An exit for the holding, not a deal SymBiosis did.
| Company | Bought by | Kind | Announced | Price |
|---|---|---|---|---|
| Spinifex Pharmaceuticals | Novartis International | Acquisition | 29 Jun 2015 | $200m+ |
| Spinifex Pharmaceuticals | Novartis | Acquisition | 29 Jun 2015 | $700m |
People
Coverage
Stories naming SymBiosis. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Series C
US$112m
AdvanCell Successfully Completes an Oversubscribed US$112M Series C Financing
Sydney cancer-therapy developer AdvanCell has completed a US$112 million Series C that was oversubscribed, co-led by four investors, with Brandon Capital among new backers; three investor representatives join the board.
3 deals
Monash team wins $US250,000 in Elon Musk-backed XPRIZE for CO2 removal
Student teams from Monash, Sydney and Tasmania universities won prize money in the XPRIZE Carbon Removal Student Competition backed by Elon Musk, with Monash's MC3 team receiving US$250,000.
2 deals
$1.67 Million Grant To Develop Pain Drug
Spinifex Pharmaceuticals won a $1.67 million federal Commercial Ready grant to advance its neuropathic pain drug, after a $3.25 million syndicate raise the previous July; it was spun out of the University of Queensland.
Unnamed stage
$3.2m
SPINIFEX SECURES $3.25 M INVESTMENT TO DEVELOP PAIN THERAPY
University of Queensland spinout Spinifex Pharmaceuticals landed $3.25 million from Symbiosis, GBS Venture Partners and Uniseed to advance its neuropathic pain therapy toward toxicology testing.
Also GBS Ventures·GBS Ventures·clinicalleader.com·bionity.com